SCHEMBL3602223

SCHEMBL3602223

[NH]c1cccc2c1NC(=O)C(CCO)O2

nearest known ligand 0.44

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.44
KMT2A Q03164 4/20 0.35
MEN1 O00255 3/20 0.35
ALDH1A1 P00352 2/20 0.34
HPGD P15428 1/20 0.34
GAA P10253 1/20 0.33
CYP3A4 P08684 1/20 0.33
TRPV1 Q8NER1 1/20 0.33
NR3C1 P04150 1/20 0.32
MAPK1 P28482 2/20 0.32
HSD17B10 Q99714 2/20 0.32
TP53 P04637 2/20 0.32
USP2 O75604 1/20 0.32
HTR1A P08908 1/20 0.31
DRD2 P14416 1/20 0.31
HTR2A P28223 1/20 0.31
MAPT P10636 1/20 0.31
THRB P10828 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7472392 0.83 L3MBTL1 (0.47) L3MBTL1KMT2AMEN1ALDH1A1HPGD
SCHEMBL3591936 0.77 L3MBTL1 (0.44) L3MBTL1KMT2AMEN1ALDH1A1HPGD
SCHEMBL5670577 0.76 L3MBTL1 (0.58) L3MBTL1KMT2AMEN1ALDH1A1HPGD
SCHEMBL3589207 0.74 PARP1 (0.56) KMT2AMEN1TP53
SCHEMBL3637630 0.74 PARP1 (0.56) KMT2AMEN1TP53
SCHEMBL3642063 0.74 PARP1 (0.56) KMT2AMEN1TP53
SCHEMBL3598938 0.71 L3MBTL1 (0.53) L3MBTL1KMT2AMEN1ALDH1A1HPGD
SCHEMBL3597209 0.71 L3MBTL1 (0.63) L3MBTL1KMT2AMEN1GAACYP3A4
SCHEMBL5802572 0.69 L3MBTL1 (0.40) L3MBTL1KMT2AMEN1CYP3A4TRPV1
SCHEMBL7471863 0.66 L3MBTL1 (0.59) L3MBTL1KMT2AMEN1ALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100016285-A1 HETEROCYCLIDENE-N-(ARYL) ACETAMIDE DERIVATIVE MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2010-01-21 US disclosed
EP-2128157-A1 HETEROCYCLIDENE-N-(ARYL)ACETAMIDE DERIVATIVE MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2009-12-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100016285-A1 HETEROCYCLIDENE-N-(ARYL) ACETAMIDE DERIVATIVE CCNY, CCND3, NSD3 L3MBTL1 1176/4885KMT2A 906/4885MEN1 2424/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.